Critical Overview of the Risk Scoring Systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome

• Published in: International journal of molecular sciences Vol. 17; no. 3; p. 278
• Main Authors: Rigante, Donato, Andreozzi, Laura, Fastiggi, Michele, Bracci, Benedetta, Natale, Marco, Esposito, Susanna
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 24.02.2016; MDPI
• Subjects: Biomarkers - blood; Biomarkers - metabolism; Child; Children & youth; Coronary Artery Disease - diagnosis; Coronary Artery Disease - epidemiology; Coronary Artery Disease - prevention & control; Coronary vessels; Humans; Immunoglobulins; Immunoglobulins - administration & dosage; Immunoglobulins - therapeutic use; Injections, Intravenous; Japan; Kawasaki disease; Mucocutaneous Lymph Node Syndrome - diagnosis; Mucocutaneous Lymph Node Syndrome - drug therapy; Mucocutaneous Lymph Node Syndrome - epidemiology; Review; Kawasaki syndrome; intravenous immunoglobulin; coronary artery abnormalities
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms17030278

Kawasaki syndrome (KS) is the most relevant cause of heart disease in children living in developed countries. Intravenous immunoglobulin (IVIG) has a preventive function in the formation of coronary artery abnormalities and a poor strictly-curative action in established coronary damage. More than two decades ago, the Harada score was set to assess which children with KS should be subject to administration of IVIG, evaluating retrospectively a large cohort of patients with regard to age, sex and laboratory data. Nowadays, high dose IVIG is administered to all children with a confirmed diagnosis of KS, but a tool for predicting non-responsiveness to the initial infusion of IVIG has not been found. The prediction of IVIG resistance is a crucial issue, as recognising these high-risk patients should consent the administration of an intensified initial treatment in combination with IVIG in order to prevent coronary injuries. Few reports have focused on factors, referring to both clinical parameters and laboratory data at the onset of KS, in order to predict which patients might be IVIG non-responsive. We have analysed three different risk scores which were formulated to predict IVIG resistance in Japanese children with typical KS, but their application in non-Japanese patients or in those with incomplete and atypical patterns of the disease has been studied in a fragmentary way. Overall, our analysis showed that early and definite ascertainment of likely IVIG non-responders who require additional therapies reducing the development of coronary artery involvement in children with KS is still a challenge.